Now enrolling pivotal Phase 3 PIONEER study in diabetic nephropathy
PYRIDORIN
in Diabetic Nephropathy
Our lead drug candidate inhibits the pathogenic oxidative chemistries that lead to diabetic nephropathy and end stage renal disease. PYRIDORIN® (pyridoxamine dihydrochloride) was shown to safely scavenge a broad range of these chemistries, which we believe accounts for its effectiveness in slowing the progression of the disease in our Phase 2 studies.
About Us
NephroGenex is an innovator in the development of drugs to treat kidney disease, with a first indication in diabetic nephropathy. Our clinical and regulatory teams positioned the Phase 3 Pyridorin program for success by securing from FDA a Fast Track designation and Special Protocol Assessment for a new endpoint and patient population. We believe Pyridorin has potential to be a breakthrough therapy in a disease for which there are few treatment options.